Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is well-positioned for success in the biotechnology industry due to its strong pipeline of precision oncology therapies, with vopimetostat and TNG456 showing promising results in clinical trials. The company's partnerships with RevMed and ERAS-0015 also demonstrate the potential for collaboration and continue innovation in the field. While there are risks associated with clinical trials and obtaining regulatory approvals, Tango Therapeutics has a strong investment value, with a DCF-based valuation estimating a 12-month price objective of $68 per share. Upcoming catalysts, such as data updates and initiations of pivotal trials, further support a positive outlook for the future of the company.

Bears say

Tango Therapeutics is facing intense competition in the biotechnology industry, particularly in the field of precision oncology therapies for the treatment of cancer. The company's pipeline products, PRMT5 and CoREST, face potential delays in FDA approval as well as significant competition from other PRMT5 drugs, particularly in the Chinese market. Additionally, potential safety concerns and slower than anticipated physician uptake could limit the company's revenues and pose downside risk to the stock and price target. With the highly competitive nature of the oncology market and potential challenges in FDA approval and market adoption, this financial analyst holds a negative outlook on Tango Therapeutics's stock performance.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.